Prevest Denpro [PREVEST] vs Dr Agarwal's Health [AGARWALEYE] Detailed Stock Comparison
Prevest Denpro
BSE
Loading...
Dr Agarwal's Health
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Prevest Denpro wins in 12 metrics, Dr Agarwal's Health wins in 5 metrics, with 0 ties. Prevest Denpro appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Prevest Denpro | Dr Agarwal's Health | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.49 | 158.88 | Prevest Denpro |
| Price-to-Book Ratio | 6.22 | 8.63 | Prevest Denpro |
| Debt-to-Equity Ratio | 0.00 | 49.87 | Prevest Denpro |
| PEG Ratio | 1.73 | N/A | N/A |
| EV/EBITDA | 25.67 | 39.85 | Prevest Denpro |
| Profit Margin (TTM) | 28.86% | 5.66% | Prevest Denpro |
| Operating Margin (TTM) | 30.58% | 13.32% | Prevest Denpro |
| EBITDA Margin (TTM) | 30.58% | 13.32% | Prevest Denpro |
| Return on Equity | 17.20% | 4.33% | Prevest Denpro |
| Return on Assets (TTM) | 16.13% | 2.27% | Prevest Denpro |
| Free Cash Flow (TTM) | $128.49M | $394.30M | Dr Agarwal's Health |
| Dividend Yield | 0.17% | N/A | N/A |
| 1-Year Return | -8.64% | 24.26% | Dr Agarwal's Health |
| Price-to-Sales Ratio (TTM) | 10.03 | 8.98 | Dr Agarwal's Health |
| Enterprise Value | $5.91B | $163.67B | Dr Agarwal's Health |
| EV/Revenue Ratio | 9.03 | 9.12 | Prevest Denpro |
| Gross Profit Margin (TTM) | 77.43% | 43.48% | Prevest Denpro |
| Revenue per Share (TTM) | $55 | $58 | Dr Agarwal's Health |
| Earnings per Share (Diluted) | $15.86 | $3.21 | Prevest Denpro |
| Beta (Stock Volatility) | 0.43 | N/A | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Prevest Denpro vs Dr Agarwal's Health Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Prevest Denpro | -0.47% | -1.01% | -6.44% | -2.72% | 7.46% | -9.26% |
| Dr Agarwal's Health | -0.49% | 2.21% | 18.47% | 21.34% | 14.60% | 24.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Prevest Denpro | -8.64% | 33.44% | 105.45% | 105.45% | 105.45% | 105.45% |
| Dr Agarwal's Health | 24.26% | 24.26% | 24.26% | 24.26% | 24.26% | 24.26% |
News Based Sentiment: Prevest Denpro vs Dr Agarwal's Health
Prevest Denpro
News based Sentiment: MIXED
September presented a mixed bag for Prevest Denpro, with short-term price increases offset by broader sector declines and persistent valuation concerns. While the company's financial stability is a positive, the negative analyst assessment and fluctuating investor participation create uncertainty, making it a moderately significant month for investors.
Dr Agarwal's Health
News based Sentiment: POSITIVE
September showcased a blend of strong financial results, strategic consolidation through increased subsidiary ownership, and ongoing merger discussions. While some concerns exist regarding the merger terms and rising interest costs, the overall narrative points towards continued growth and positive investor sentiment, making it a significant month for the company.
Performance & Financial Health Analysis: Prevest Denpro vs Dr Agarwal's Health
| Metric | PREVEST | AGARWALEYE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.65B | ₹157.95B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 2,840 | 388,339 |
| 90 Day Avg. Volume | 8,133 | 283,769 |
| Last Close | ₹544.45 | ₹499.60 |
| 52 Week Range | ₹393.60 - ₹686.00 | ₹327.00 - ₹515.00 |
| % from 52W High | -20.63% | -2.99% |
| All-Time High | ₹686.00 (Jan 13, 2025) | ₹515.00 (Oct 01, 2025) |
| % from All-Time High | -20.63% | -2.99% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.21% |
| Quarterly Earnings Growth | 0.20% | 1.51% |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | 0.06% |
| Operating Margin (TTM) | 0.31% | 0.13% |
| Return on Equity (TTM) | 0.17% | 0.04% |
| Debt to Equity (MRQ) | 0.00 | 49.87 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹87.89 | ₹59.09 |
| Cash per Share (MRQ) | ₹54.65 | ₹16.23 |
| Operating Cash Flow (TTM) | ₹185.37M | ₹1.43B |
| Levered Free Cash Flow (TTM) | ₹181.55M | ₹834.60M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.17% | N/A |
| Last 12-Month Dividend | ₹1.00 | N/A |
Valuation & Enterprise Metrics Analysis: Prevest Denpro vs Dr Agarwal's Health
| Metric | PREVEST | AGARWALEYE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.49 | 158.88 |
| Forward P/E | N/A | 89.83 |
| PEG Ratio | 1.73 | N/A |
| Price to Sales (TTM) | 10.03 | 8.98 |
| Price to Book (MRQ) | 6.22 | 8.63 |
| Market Capitalization | ||
| Market Capitalization | ₹6.65B | ₹157.95B |
| Enterprise Value | ₹5.91B | ₹163.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.03 | 9.12 |
| Enterprise to EBITDA | 25.67 | 39.85 |
| Risk & Other Metrics | ||
| Beta | 0.43 | N/A |
| Book Value per Share (MRQ) | ₹87.89 | ₹59.09 |
Financial Statements Comparison: Prevest Denpro vs Dr Agarwal's Health
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PREVEST | AGARWALEYE |
|---|---|---|
| Revenue/Sales | ₹157.66M | ₹4.87B |
| Cost of Goods Sold | ₹35.59M | ₹2.75B |
| Gross Profit | ₹122.08M | ₹2.12B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹48.22M | ₹649.10M |
| EBITDA | ₹64.79M | ₹1.41B |
| Pre-Tax Income | ₹59.88M | ₹536.00M |
| Income Tax | ₹15.83M | ₹155.40M |
| Net Income (Profit) | ₹44.05M | ₹380.60M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PREVEST | AGARWALEYE |
|---|---|---|
| Cash & Equivalents | ₹608.98M | ₹1.04B |
| Total Current Assets | ₹857.15M | ₹7.94B |
| Total Current Liabilities | ₹59.62M | ₹4.78B |
| Long-Term Debt | ₹0 | ₹8.08B |
| Total Shareholders Equity | ₹1.06B | ₹19.27B |
| Retained Earnings | ₹733.61M | N/A |
| Property, Plant & Equipment | ₹13.99M | ₹13.40B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PREVEST | AGARWALEYE |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PREVEST | AGARWALEYE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,840 | 388,339 |
| Average Daily Volume (90 Day) | 8,133 | 283,769 |
| Shares Outstanding | 12.00M | 315.88M |
| Float Shares | 2.48M | 53.12M |
| % Held by Insiders | 0.78% | 0.76% |
| % Held by Institutions | 0.00% | 0.18% |
Dividend Analysis & Yield Comparison: Prevest Denpro vs Dr Agarwal's Health
| Metric | PREVEST | AGARWALEYE |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | N/A |
| Last 12-Month Dividend Yield | 0.17% | N/A |
| 3-Year Avg Annual Dividend | ₹0.33 | N/A |
| 3-Year Avg Dividend Yield | 0.17% | N/A |
| 3-Year Total Dividends | ₹1.00 | N/A |
| Ex-Dividend Date | Sep 03, 2025 | N/A |